saascode
biotech, life sciences & pharma·run 021 · Apr 2026

Cragrid

A clinical-research associate workspace that links study and site plans, visit evidence, follow-up commitments, document reminders, corrections, and source-system acknowledgements under sponsor-controlled validation.

Genesis score0.00/10
Make Cragrid real.0/500
500 more votes and Cragrid is authorized for build.
0%500 to authorize
Backing is the vote. When an idea crosses 500, we pull it into the build pipeline and ship it for real — the votes decide what gets built next, not an editor.
The case

Clinical-research associates may coordinate site visits across notes, calendars, spreadsheets, email, and sponsor systems. Cragrid proposes one operational record without claiming to replace the clinical-trial management system or arrive prevalidated. Vendor test evidence can support a sponsor's risk-based validation, but intended use, configuration, procedures, qualification, acceptance, and ongoing control remain customer responsibilities.

Who pays — and why

A clinical operations or monitoring leader at a sponsor, contract research organization, or research team managing multiple sites. The source explicitly lacks a validated buyer and budget.

Market signal$49-$99/user/mo was proposed for the concept; an adjacent full clinical-trial system was observed from roughly $599/mo.Observed market reference, not fixed product pricing
What it unlocks
A study-site-visit record linking plan, schedule, evidence, finding candidate, owner, due date, correction, and closure review
A vendor evidence pack with requirements, traceability, tests, results, limitations, version, and change history
Explicit sponsor approval for intended use, configuration, procedures, roles, and release
Separate connector command, destination acknowledgement, source-system readback, inspection finding, and study outcome
How Genesis scored it
0.00across seven criteria
tension 7temporal 8blindspot 5buyer 4leverage 7convergence 5why-not 7
8
Temporal window

Recent guidance and inspection concern create a current operating signal.

7
Productive tension

A lightweight workflow is useful only if it preserves regulated records, review, and customer validation authority.

4
Buyer persona

The source explicitly lacks a validated buyer despite plausible monitoring roles.

Why it scored well

A recent practitioner signal, updated clinical guidance, and two confirmed interfaces support timing and viability. The focused tracker sits between general notes and a full clinical-trial system.

What's holding it back

The stored score is zero and the source explicitly reports no buyer. Validation is customer- and intended-use-specific, enterprise connector access requires licenses, competition exists, and no structural incumbent disadvantage is proven.

Signals detected3 sources crossed
SignalSimpleTrials product and pricing review

SignalVeeva Vault developer portal review

SignalGenesis competitive review

Direction briefcragrid.md
cragrid.md
Want this pointed at your vertical?Point Genesis at your own market and constraints — it invents adjacent, fork-ready ideas, private to you before they hit the public feed.

Discussion

?

No comments yet — be the first to weigh in.